Evidence map›Paper›PMID 40143346›Full record

ReviewViruses2025

Structural Virology: The Key Determinants in Development of Antiviral Therapeutics.

Tanuj Handa, Ankita Saha, Aarthi Narayanan, Elsa Ronzier, Pravindra Kumar, Jitin Singla, Shailly Tomar

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tanuj HandaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.ORCID 0000-0003-0370-7522
Ankita SahaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.ORCID 0009-0004-4791-3322
Aarthi NarayananDepartment of Biology, College of Science, George Mason University, Fairfax, VA 22030, USA.
Elsa RonzierBiomedical Research Laboratory, Institute for Biohealth Innovation, George Mason University, Fairfax, VA 22030, USA.ORCID 0000-0003-1008-4271
Pravindra KumarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.
Jitin SinglaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.ORCID 0000-0001-6225-0783
Shailly TomarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Roorkee 247667, India.

Funding

Scheme for Transformational and Advanced Research in Sciences (STARS), Ministry of Education (MoE), India STARS2/2023-0209
6 · The paper itself

Abstract

Structural virology has emerged as the foundation for the development of effective antiviral therapeutics. It is pivotal in providing crucial insights into the three-dimensional frame of viruses and viral proteins at atomic-level or near-atomic-level resolution. Structure-based assessment of viral components, including capsids, envelope proteins, replication machinery, and host interaction interfaces, is instrumental in unraveling the multiplex mechanisms of viral infection, replication, and pathogenesis. The structural elucidation of viral enzymes, including proteases, polymerases, and integrases, has been essential in combating viruses like HIV-1 and HIV-2, SARS-CoV-2, and influenza. Techniques including X-ray crystallography, Nuclear Magnetic Resonance spectroscopy, Cryo-electron Microscopy, and Cryo-electron Tomography have revolutionized the field of virology and significantly aided in the discovery of antiviral therapeutics. The ubiquity of chronic viral infections, along with the emergence and reemergence of new viral threats necessitate the development of novel antiviral strategies and agents, while the extensive structural diversity of viruses and their high mutation rates further underscore the critical need for structural analysis of viral proteins to aid antiviral development. This review highlights the significance of structure-based investigations for bridging the gap between structure and function, thus facilitating the development of effective antiviral therapeutics, vaccines, and antibodies for tackling emerging viral threats.

Indexed as

Antiviral AgentsVirus DiseasesVirusesAnimalsCryoelectron MicroscopyCrystallography, X-RayDrug DevelopmentDrug DiscoveryHumansSARS-CoV-2Viral ProteinsAntiviral AgentsViral Proteinsantiviral therapeuticsbioinformaticscryo-EMemerging and reemerging virusesnuclear magnetic resonance (NMR)rational drug designstructural virologyviral proteinsviral replication enzymesX-ray crystallography

Identifiers

PMID40143346
PMCPMC11945554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.